open access

Vol 13, No 5 (2008)
Untitled
Published online: 2008-09-01
Submitted: 2008-05-06
Get Citation

CT-image based conformal high-dose-rate brachytherapy boost in the conservative treatment of stage I – II breast cancer – introducing the procedure

Magda KUBASZEWSKA, Magdalena DYMNICKA, Janusz SKOWRONEK, Adam CHICHEŁ, Marek KANIKOWSKI
DOI: 10.1016/S1507-1367(10)60092-2
·
Rep Pract Oncol Radiother 2008;13(5):227-239.

open access

Vol 13, No 5 (2008)
Untitled
Published online: 2008-09-01
Submitted: 2008-05-06

Abstract

Aim

Breast-conserving surgery (BCS) followed by radiotherapy (RT) has become the standard treatment for the majority of patients with early breast cancer. With regard to boost technique some disagreements are found between groups that are emphasizing the value of electron boost treatment and groups pointing out the value of interstitial brachytherapy (BT) boost treatment. We present the preliminary results in treating selected patients with early-stage breast cancer using high-dose-rate brachytherapy (HDR-BT) as a boost after breast conservation therapy (BCT).

Materials/Methods

Between January 2006 and August 2007, a total of 58 female patients with first and second stage breast cancer underwent BCT. This therapeutic procedure involves BCS, whole breast radiation therapy (WBRT) and additional irradiation to the tumour bed (boost) using interstitial HDR-BT via flexible implant tubes. A 10 Gy boost dose was received by all patients. The treatment planning was based on CT-guided 3D (three-dimensional) reconstruction of the surgical clips, implant tubes and critical structures localization (skin and ribs). The accuracy of tumour bed localization, the conformity of planning target volume and treated volume were analyzed.

Results

The evaluations of implant parameters involved the use of: dose volume histogram (DVH), the volume encompassed by the 100% reference isodose surface (V100%), the high dose volume calculation (V150%, V200%, V300%), the dose non-uniformity ratio (DNR), and the conformity index (COIN). Our results were as follows: the mean PTV volume, the mean high dose volume (V150%; V200%; V300%), the DNR and COIN mean value were estimated at 57.38, 42.98, 21.38, 7.90, 0.52 and 0.83 respectively.

Conclusions

CT-guided 3D HDR-BT is most appropriate for planning the boost procedure after BT especially in large breast volume, in cases with a deep seated tumour bed, as well as in patients with high risk for local recurrences. This technique reduces the possibility of geographical miss. Moreover, better conformity could be achieved between planning the target volume and the treated volume, even at the cost of worse dose homogeneity. The irregular 3D shape of the target volume and the normal tissue structures can be correctly localized on the basis of visual information obtained from cross-sectional CT imaging. Better local control rate with fewer side effects might be achieved with this technique based on CT imaging.

Abstract

Aim

Breast-conserving surgery (BCS) followed by radiotherapy (RT) has become the standard treatment for the majority of patients with early breast cancer. With regard to boost technique some disagreements are found between groups that are emphasizing the value of electron boost treatment and groups pointing out the value of interstitial brachytherapy (BT) boost treatment. We present the preliminary results in treating selected patients with early-stage breast cancer using high-dose-rate brachytherapy (HDR-BT) as a boost after breast conservation therapy (BCT).

Materials/Methods

Between January 2006 and August 2007, a total of 58 female patients with first and second stage breast cancer underwent BCT. This therapeutic procedure involves BCS, whole breast radiation therapy (WBRT) and additional irradiation to the tumour bed (boost) using interstitial HDR-BT via flexible implant tubes. A 10 Gy boost dose was received by all patients. The treatment planning was based on CT-guided 3D (three-dimensional) reconstruction of the surgical clips, implant tubes and critical structures localization (skin and ribs). The accuracy of tumour bed localization, the conformity of planning target volume and treated volume were analyzed.

Results

The evaluations of implant parameters involved the use of: dose volume histogram (DVH), the volume encompassed by the 100% reference isodose surface (V100%), the high dose volume calculation (V150%, V200%, V300%), the dose non-uniformity ratio (DNR), and the conformity index (COIN). Our results were as follows: the mean PTV volume, the mean high dose volume (V150%; V200%; V300%), the DNR and COIN mean value were estimated at 57.38, 42.98, 21.38, 7.90, 0.52 and 0.83 respectively.

Conclusions

CT-guided 3D HDR-BT is most appropriate for planning the boost procedure after BT especially in large breast volume, in cases with a deep seated tumour bed, as well as in patients with high risk for local recurrences. This technique reduces the possibility of geographical miss. Moreover, better conformity could be achieved between planning the target volume and the treated volume, even at the cost of worse dose homogeneity. The irregular 3D shape of the target volume and the normal tissue structures can be correctly localized on the basis of visual information obtained from cross-sectional CT imaging. Better local control rate with fewer side effects might be achieved with this technique based on CT imaging.

Get Citation

Keywords

breast-conserving therapy; radiotherapy; HDR brachytherapy; boost; CT-based treatment planning

About this article
Title

CT-image based conformal high-dose-rate brachytherapy boost in the conservative treatment of stage I – II breast cancer – introducing the procedure

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 13, No 5 (2008)

Pages

227-239

Published online

2008-09-01

DOI

10.1016/S1507-1367(10)60092-2

Bibliographic record

Rep Pract Oncol Radiother 2008;13(5):227-239.

Keywords

breast-conserving therapy
radiotherapy
HDR brachytherapy
boost
CT-based treatment planning

Authors

Magda KUBASZEWSKA
Magdalena DYMNICKA
Janusz SKOWRONEK
Adam CHICHEŁ
Marek KANIKOWSKI

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl